Your session is about to expire
← Back to Search
Neurotoxin
Botulinum Toxin type A for Headache Disorders
Phase < 1
Waitlist Available
Led By Yoly M Gonzalez-Stucker, DDS, MS, MPH
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adults age 18 to 74 years old.
Participants with Headaches Attributed to TMD based on Diagnostic Criteria for TMD (DC-TMD) criteria.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 12 weeks up to 1 year
Awards & highlights
Study Summary
This study will evaluate the effect of of botulinum toxin on the treatment of Headache Attributed to TMD.
Eligible Conditions
- Headache Disorders
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ every 12 weeks up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 12 weeks up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pain
Reduction in Headache Impact Test-6 score (HIT-6)
Reduction in number of Headaches Attributed to TMD (HA)
Secondary outcome measures
Graded Chronic Pain Scale (GCPS), 1 and 6 months score
Jaw Functional Limitation Scale
Temporomandibular Joint Disorders
Side effects data
From 2012 Phase 3 trial • 196 Patients • NCT013137674%
Nasopharyngitis
4%
Pain in extremity
3%
Diarrhoea
3%
Vomiting
3%
Back pain
3%
Oedema peripheral
2%
Cholecystitis acute
2%
Abdominal distension
2%
Dyspepsia
2%
Nausea
2%
Upper respiratory tract infection
2%
Musculoskeletal pain
2%
Injection site haematoma
2%
Pyrexia
1%
Hepatitis toxic
1%
Intraventricular haemorrhage
1%
Pulmonary tuberculosis
1%
Renal failure
1%
Consitipation
1%
Dizziness
1%
Headache
1%
Myocardial infarction
1%
Pneumonia
1%
Convulsion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Meditoxin®
Botox®
Trial Design
1Treatment groups
Experimental Treatment
Group I: Botulinum Toxin type AExperimental Treatment1 Intervention
Participants will be injected intramuscularly with total of 50 Units, 25 units of Botulinum A per temporalis muscle. The BTX injection will be prepared by dissolving 100 U vial in 2 ml of 0.9 % of Sodium Chloride (NaCl), yielding 25 U/ml. Each participant will receive 0.1 ml of BTX/NaCl mixture in 5 spots per temporalis muscle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Botulinum toxin type A
FDA approved
Find a Location
Who is running the clinical trial?
State University of New York at BuffaloLead Sponsor
245 Previous Clinical Trials
49,448 Total Patients Enrolled
Yoly M Gonzalez-Stucker, DDS, MS, MPHPrincipal InvestigatorUniversity at Buffalo
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger